Oriola Oyj ORIOLA.HE
Nasdaq Helsinki · Healthcare · Pharmaceutical Retailers
0.79 EUR
+1.4%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Oriola
| EUR million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 1,539 | 1,494 | 1,680 | 1,906 |
| EBITDA | 34 | 23 | −1 | −6 |
| Net income | −2 | −21 | −20 | −27 |
| Balance sheet | ||||
| Equity | 226 | 171 | 133 | 101 |
| Total debt | 137 | 118 | 76 | 70 |
| Cash | 161 | 138 | 114 | 152 |
| Net debt | −24 | −21 | −37 | −82 |
| Ratios and per share | ||||
| EBITDA margin | 2.2% | 1.5% | −0.0% | −0.3% |
| Profit margin | −0.2% | −1.4% | −1.2% | −1.4% |
| Return on equity | −1.1% | −12.1% | −15.1% | −27.0% |
| Earnings/share (EUR) | −0.01 | −0.11 | −0.11 | −0.15 |
| Book value/share (EUR) | 1.24 | 0.94 | 0.74 | 0.54 |
| Shares outstanding (M) | 181 | 181 | 181 | 185 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | – |
| P/B | 1.4 |
| EV / EBITDA | – |
| Net debt / EBITDA | – |
| Return on equity | −27.0% |
| Profit margin | −1.4% |
| Beta 1Y | 0.25 |
| Revenue growth 1Y | +13.5% |
| Revenue CAGR 3Y | +7.4% |
| ROE avg. 3Y | −18.0% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (EUR)
| 2026 | 0.03 |
| 2025 | 0.07 |
| 2024 | 0.07 |
| 2023 | 0.06 |
| 2022 | 0.04 |
Not investment advice. Figures may contain errors from the data source.